Core Insights - The National Healthcare Security Administration (NHSA) announced that as of January 11, 2026, 105 newly negotiated drugs will be available in 11,129 designated medical institutions across the country, including 6,537 medical institutions and 4,592 retail pharmacies [1] - Additionally, 19 innovative commercial insurance drugs will be available in 965 designated medical institutions, comprising 449 medical institutions and 516 retail pharmacies [1] - The NHSA has organized relevant companies to submit lists of institutions equipped with the newly negotiated drugs and innovative commercial insurance drugs for the 2025 version of the medical insurance catalog [1] Summary by Category Negotiated Drugs - Out of the 105 newly negotiated drugs, 88 have available institution information [1] - The NHSA will focus on monitoring and guiding companies to ensure the availability of drugs that have not yet been equipped in designated medical institutions, thereby safeguarding the medication rights of insured individuals [1] Innovative Commercial Insurance Drugs - Among the 19 innovative commercial insurance drugs, 16 have available institution information [1] - The data regarding the equipped institutions for both negotiated and innovative drugs is published on the NHSA's official website and the National Medical Insurance Service Platform App for insured individuals to access [1]

Core Insights - The National Healthcare Security Administration (NHSA) is facilitating the implementation of negotiated drugs in the 2025 medical insurance catalog, providing a list of new negotiated drugs and innovative commercial insurance drugs for 2025 [1][2] Group 1: New Drug Distribution - As of January 11, 2026, 105 new negotiated drugs have been included in the medical insurance catalog, distributed across 11,129 designated medical institutions nationwide [1] - Among the 105 new negotiated drugs, 88 have available distribution information, with two drugs, namely Increlex and Liposomal Irinotecan, available in all 31 provinces and the Xinjiang Production and Construction Corps [1] - 20 drugs are available in more than 30 provinces, 53 drugs in more than 20 provinces, and 67 drugs in more than 10 provinces [1] Group 2: Commercial Insurance Drugs - There are 19 innovative commercial insurance drugs, with 16 having distribution information, and the drug Ipilimumab is available in over 30 provinces [1] - Seven commercial insurance drugs are distributed in more than 20 provinces, and 12 drugs are available in more than 10 provinces [1] Group 3: Monitoring and Compliance - The NHSA will focus on monitoring drugs that have not yet been distributed to designated medical institutions, ensuring that companies comply with distribution requirements to protect the medication rights of insured individuals [2]